[Experimental study of sulpiride-bromocriptine association on the female rat estrous cycle (author's transl)].
Mikaeel Valli, B Bruguerolle, Guy Jadot, Pierre Bouyard
Abstract
Mikaeel Valli, B Bruguerolle, Guy Jadot, Pierre Bouyard
Abstract
The effects of joint treatment by sulpiride (1 mg . kg-1 S.C. pro die) and bromocriptine (3 mg . kg-1 S.C. pro die) on female rat estrous cycles were carried out on a group of ninety animals for a twenty-one days period. The results thus obtained show that: (i) bromocriptine alone does not disturb the estrous cycle, (ii) when given both with sulpiride, it prevents from this psycholeptic's estrous cycle blockade, (iii) finally, it leads to the regression of a blockade induced by an eight days sulpiride pretreatment. Therefore, it is likely that these two drugs act antagonistically at tuberoinfundibular dopaminergic receptors involved in the prolactin and gonadotropins release.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The effects of joint treatment by sulpiride (1 mg . kg-1 S.C. pro die) and bromocriptine (3 mg . kg-1 S.C. pro die) on female rat estrous cycles were carried out on a group of ninety animals for a twenty-one days period. The results thus obtained show that: (i) bromocriptine alone does not disturb the estrous cycle, (ii) when given both with sulpiride, it prevents from this psycholeptic's estrous cycle blockade, (iii) finally, it leads to the regression of a blockade induced by an eight days sulpiride pretreatment. Therefore, it is likely that these two drugs act antagonistically at tuberoinfundibular dopaminergic receptors involved in the prolactin and gonadotropins release.
Key concepts: Bromocriptine, Sulpiride, Estrous cycle, Prolactin, Dopaminergic, Endocrinology, Internal medicine, Blockade